Prothena (PRTA) Projected to Post Quarterly Earnings on Thursday

Prothena (NASDAQ:PRTA) is projected to announce its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Prothena to post earnings of ($0.45) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Prothena Price Performance

Shares of PRTA opened at $8.93 on Thursday. The company has a market capitalization of $480.70 million, a P/E ratio of -1.71, a P/E/G ratio of 1.89 and a beta of -0.11. Prothena has a 1-year low of $4.32 and a 1-year high of $16.67. The firm’s 50 day simple moving average is $9.48 and its 200 day simple moving average is $9.31.

Institutional Investors Weigh In On Prothena

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Intech Investment Management LLC raised its position in Prothena by 5.5% during the 3rd quarter. Intech Investment Management LLC now owns 19,388 shares of the biotechnology company’s stock valued at $189,000 after purchasing an additional 1,014 shares in the last quarter. Brooklyn Investment Group lifted its position in shares of Prothena by 13.1% in the 3rd quarter. Brooklyn Investment Group now owns 12,569 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 1,456 shares during the period. Deutsche Bank AG increased its holdings in Prothena by 5.1% during the fourth quarter. Deutsche Bank AG now owns 35,482 shares of the biotechnology company’s stock valued at $339,000 after buying an additional 1,709 shares during the period. Franklin Resources Inc. boosted its position in Prothena by 9.1% during the 3rd quarter. Franklin Resources Inc. now owns 61,172 shares of the biotechnology company’s stock valued at $597,000 after acquiring an additional 5,094 shares in the last quarter. Finally, Raymond James Financial Inc. lifted its stake in shares of Prothena by 63.2% during the 3rd quarter. Raymond James Financial Inc. now owns 22,032 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 8,536 shares during the last quarter. Institutional investors own 97.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on PRTA shares. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on shares of Prothena in a research report on Monday, December 1st. Piper Sandler lifted their target price on Prothena from $15.00 to $36.00 and gave the stock an “overweight” rating in a report on Tuesday, October 28th. Citigroup reissued a “market outperform” rating on shares of Prothena in a report on Monday, December 1st. Wall Street Zen raised Prothena from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prothena in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $21.56.

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.